Scoping review on dosing of anaesthetic and perioperative drugs in patients with obesity: which body weight for which molecule.
Gouel-Chéron Aurélie A, Aubrun Frédéric F, Aubrun Frédéric F, Garnier Marc M et al.
The prevalence of obesity is rising. Patients with obesity are increasingly exposed to anaesthesia, critical care, and perioperative pharmacotherapy. Obesity alters drug pharmacokinetics in a non-linear, drug-specific manner, so that simply scaling doses to total body weight (TBW) exposes patients to overdose or underdose. A recurring clinical question is therefore: which body weight descriptor should be used for which molecule? This review was conducted in accordance with the PRISMA extension for Scoping Reviews. We synthesized pharmacokinetic evidence, recent meta-analyses, and French and European guidelines on dose adjustment in adults with obesity for five drug classes of anaesthesia and critical care: hypnotics, opioids, neuromuscular blocking agents (NMBA), perioperative antibiotics, and non-opioid analgesics. We summarised the recommended dosing weight for each molecule in a table and a figure. No single weight descriptor applies. Lipophilic induction agents (propofol), most opioids (alfentanil, fentanyl, sufentanil), and non-depolarising NMBA are best dosed on lean or ideal body weight, whereas succinylcholine, neuromuscular reversal, and aminoglycosides use total or adjusted body weight. Maintenance of hypnosis and pain management in the post-anaesthesia care unit are titrated to monitored effect. Cephalosporin-based antibiotic prophylaxis relies on fixed doses (e.g., cefazolin 2 g) up to high body mass index values due to their hydrophilic properties. Paracetamol and non-steroidal anti-inflammatory drugs are given at standard doses and never scaled to TBW. Findings are consolidated in a single bedside reference table. Dosing in obesity must be molecule-specific, guided by the relevant weight descriptor and by intraoperative monitoring rather than by TBW alone.